Committed to the Preservation of Vision

At Outlook Therapeutics, we are redefining the standard of care for retinal diseases, including wet age-related macular degeneration (wet AMD).

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Our Vision

Driven by the stories of those we serve, Outlook Therapeutics is focused on delivering quality and accessibility in retinal care. United in purpose with the vision care community, we prioritize a future where all patients with retinal disease can envision a brighter world.

Explore the potential of ONS-5010, a first-of-its-kind ophthalmic formulation of bevacizumab.